Zoetis (ZTS) Receivables (2012 - 2026)
Zoetis' (ZTS) quarterly Receivables came in at $1.5 billion in Q1 2026, up 10.65% year-on-year from $1.4 billion in Q1 2025, and up 1.89% on a QoQ basis from $1.5 billion in Q4 2025.
Zoetis (ZTS) Receivables (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Receivables data on file, last reported at $1.5 billion in Q1 2026.
- On a quarterly basis, Receivables rose 10.65% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 10.65% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 18.92% from the prior year.
- Receivables for Q1 2026 stood at $1.5 billion, up from $1.5 billion in the prior quarter.
- Over the last five years, Receivables for ZTS reached as high as $1.5 billion in Q3 2025 and fell as low as $1.2 billion in Q1 2023.
- Historically, Receivables has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
- Across the five-year window, Receivables declined 2.95% in 2023 and gained 12.25% in 2024, its largest moves.
- Year by year, Receivables stood at $1.3 billion in 2022, then gained by 5.91% to $1.4 billion in 2023, then climbed by 2.42% to $1.4 billion in 2024, then climbed by 5.95% to $1.5 billion in 2025, then climbed by 1.89% to $1.5 billion in 2026.
- Per Business Quant data, the three most recent Receivables figures were $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Bn |
| Dec 31, 2025 | 1.48 Bn |
| Sep 30, 2025 | 1.54 Bn |
| Jun 30, 2025 | 1.54 Bn |
| Mar 31, 2025 | 1.36 Bn |
| Dec 31, 2024 | 1.40 Bn |
| Sep 30, 2024 | 1.41 Bn |
| Jun 30, 2024 | 1.38 Bn |
| Mar 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 1.36 Bn |
| Sep 30, 2023 | 1.26 Bn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.19 Bn |
| Dec 31, 2022 | 1.29 Bn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.29 Bn |
| Mar 31, 2022 | 1.22 Bn |
| Dec 31, 2021 | 1.18 Bn |
| Sep 30, 2021 | 1.15 Bn |
| Jun 30, 2021 | 1.17 Bn |